AgenciesManufacturers of remdesivir in India have voluntarily slashed prices after the government intervened, amid shortage of anti viral injection in the country.
The National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals announced on Saturday the change in prices for seven brands of remdesivir injections of potency 100mg per vial. According to an office memorandum by NPPA dated April 17, the prices have been slashed in the range of ₹1,000 to ₹2,700.
The announcement came, following a recent meeting. Minister of State for Chemicals and Fertilisers Mansukh Mandaviya held meetings with drug manufacturers and other stakeholders on April 12 and 13 in which decisions were taken to increase production and reduce prices of remdesivir.
Cadila Healthcare's Remdac continues to be the cheapest remdesivir injection priced at ₹899. The injection was earlier being sold at ₹2,800.
RemWin by Bharat Biologics India's Syngene International is now available at ₹2,450 instead of ₹3,950. Redyx by Dr Reddy’s Laboratories will now cost ₹2,700, half of its earlier price of ₹5,400. Cipla has slashed the price for its Cipremi to ₹3,000 from ₹4,000.
The National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals announced on Saturday the change in prices for seven brands of remdesivir injections of potency 100mg per vial. According to an office memorandum by NPPA dated April 17, the prices have been slashed in the range of ₹1,000 to ₹2,700.
The announcement came, following a recent meeting. Minister of State for Chemicals and Fertilisers Mansukh Mandaviya held meetings with drug manufacturers and other stakeholders on April 12 and 13 in which decisions were taken to increase production and reduce prices of remdesivir.
Cadila Healthcare's Remdac continues to be the cheapest remdesivir injection priced at ₹899. The injection was earlier being sold at ₹2,800.
RemWin by Bharat Biologics India's Syngene International is now available at ₹2,450 instead of ₹3,950. Redyx by Dr Reddy’s Laboratories will now cost ₹2,700, half of its earlier price of ₹5,400. Cipla has slashed the price for its Cipremi to ₹3,000 from ₹4,000.
According to the memorandum, Mylan Pharmaceutical has revised the price for its remdesivir injection Desrem to ₹3,400 from ₹4,800. Jubilant Generics has reduced the price of its offering Jubi-R to ₹3,400 from ₹4,700. Hetero Healthcare will sell its remdesivir injection Covifor at ₹3,490 instead of ₹5,400.
( Originally published on Apr 17, 2021 )
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
8 Comments on this Story
 | Sushil Srivastava5 hours ago IF CADILA ZYDUS CAN MARKET AT LESS THAN 1000 RS.WHY OTHER COS.ARE ALLOWED TO MKT AT HIGHER PRICE. IN 70_80 THERE USED TO BE A LEADER PRICE WHERE NO MFG.CO COULD MARLET ABOVE LEADER PRICE. |
 | Subbu India6 hours ago Pharma Companies make huge profit out of their products. Imagine how much profit they have made from Remdesivir when they can bring down the price from about 3K to 1K. They sre not loosing when they are selling @1K |
 | Hemant Pisat10 hours ago Pharmaceutical industry has been most convenient looter in our country. Every medicine has escalating retail price every 2 months. And this is fairly acceptable by Pharmaceutical Price Regulatory authorities, this is nothing but hand in glove profiting. Watch your medicine prices, you will realise. Reduction in Remdesivir prices now is an act of political significance. 100%. |
